Please Scroll Down to See Forums Below
Does injection site effect half life?
- Thread starter steelmass
- Start date
kidd73
Active member
Can you post up where you read this? Maybe post up the article. I've never heard of such a thing.
bblazer
Banned
Half life is half life. Are you sure you are not talking about absorption rates?
Half life is how long it takes for half of the chemical to (in this case) metabolize. This can only happen once it gets into the bloodstream. Absorption rate is how long it (again in this case) takes for it to get into the bloodstream.
I would like to see an article that talks about injection sites having the power to affect chemical half lives.
B-
Half life is how long it takes for half of the chemical to (in this case) metabolize. This can only happen once it gets into the bloodstream. Absorption rate is how long it (again in this case) takes for it to get into the bloodstream.
I would like to see an article that talks about injection sites having the power to affect chemical half lives.
B-
lookinfit75
New member
I think he means absorbtion rates although I remember EddyM talking about hitting deifferent areas for extending the effect of certain compounds. The bigger the muscle, the more blood flows through it right?
I would like to see a article on this.
The answer is no.
How do I figure out daily mg levels active in the blood,so I can keep steroid levels steady and saturated without overusing them.In the Anabolic Game Plan,Dino Strong talks about injecting steroids with slow esters into the glutes to reduce their half life...because of quicker absorption into the blood stream.
Last edited:
A
ALIN
Guest
Ive never heard this before. I dont see how it would make a difference.
bblazer
Banned
That is either a technical writing error, or bad info. It doesn't matter where an injection is given, half life remains the same. Absorption rates and half lives are two completely different things.
Absorption rate is the rate at which a chemical (in this cas AAS) is absorbed into the bloodstream.
Half life is the time it takes for the body to use, reduce, or eliminate in some way half of that chemical. For example taking 50 mg of a compound, and then how long it takes for half of that dose to remain in the system.
B-
For those that said no you may find this interesting:
Pharmacokinetics and pharmacodynamics of nandrolon... [J Pharmacol Exp Ther. 1997] - PubMed result
Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume.
Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ.
Department of Anaesthesia and Pain Management, Royal North Shore Hospital, University of Sydney, Australia.
We studied healthy men who underwent blood sampling for plasma nandrolone, testosterone and inhibin measurements before and for 32 days after a single i.m. injection of 100 mg of nandrolone ester in arachis oil. Twenty-three men were randomized into groups receiving nandrolone phenylpropionate (group 1, n = 7) or nandrolone decanoate (group 2, n = 6) injected into the gluteal muscle in 4 ml of arachis oil vehicle or nandrolone decanoate in 1 ml of arachis oil vehicle injected into either the gluteal (group 3, n = 5) or deltoid (group 4, n = 5) muscles. Plasma nandrolone, testosterone and inhibin concentrations were analyzed by a mixed-effects indirect response model. Plasma nandrolone concentrations were influenced (P < .001) by different esters and injection sites, with higher and earlier peaks with the phenylpropionate ester, compared with the decanoate ester. After nandrolone decanoate injection, the highest bioavailability and peak nandrolone levels were observed with the 1-ml gluteal injection. Plasma testosterone concentrations were also influenced (P < .001) by the ester and injection site, with the most rapid, but briefest, suppression being due to the phenylpropionate ester, whereas the most sustained suppression was achieved with the 1-ml gluteal injection. Plasma inhibin concentrations were also significantly influenced by injection volume and site, with the lowest nadir occurring after the nandrolone decanoate 1-ml gluteal injection. Thus, the bioavailability and physiological effects of a nandrolone ester in an oil vehicle are greatest when the ester is injected in a small (1 ml vs. 4 ml) volume and into the gluteal vs. deltoid muscle. We conclude that the side-chain ester and the injection site and volume influence the pharmacokinetics and pharmacodynamics of nandrolone esters in an oil vehicle in men.
Pharmacokinetics and pharmacodynamics of nandrolon... [J Pharmacol Exp Ther. 1997] - PubMed result
Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume.
Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ.
Department of Anaesthesia and Pain Management, Royal North Shore Hospital, University of Sydney, Australia.
We studied healthy men who underwent blood sampling for plasma nandrolone, testosterone and inhibin measurements before and for 32 days after a single i.m. injection of 100 mg of nandrolone ester in arachis oil. Twenty-three men were randomized into groups receiving nandrolone phenylpropionate (group 1, n = 7) or nandrolone decanoate (group 2, n = 6) injected into the gluteal muscle in 4 ml of arachis oil vehicle or nandrolone decanoate in 1 ml of arachis oil vehicle injected into either the gluteal (group 3, n = 5) or deltoid (group 4, n = 5) muscles. Plasma nandrolone, testosterone and inhibin concentrations were analyzed by a mixed-effects indirect response model. Plasma nandrolone concentrations were influenced (P < .001) by different esters and injection sites, with higher and earlier peaks with the phenylpropionate ester, compared with the decanoate ester. After nandrolone decanoate injection, the highest bioavailability and peak nandrolone levels were observed with the 1-ml gluteal injection. Plasma testosterone concentrations were also influenced (P < .001) by the ester and injection site, with the most rapid, but briefest, suppression being due to the phenylpropionate ester, whereas the most sustained suppression was achieved with the 1-ml gluteal injection. Plasma inhibin concentrations were also significantly influenced by injection volume and site, with the lowest nadir occurring after the nandrolone decanoate 1-ml gluteal injection. Thus, the bioavailability and physiological effects of a nandrolone ester in an oil vehicle are greatest when the ester is injected in a small (1 ml vs. 4 ml) volume and into the gluteal vs. deltoid muscle. We conclude that the side-chain ester and the injection site and volume influence the pharmacokinetics and pharmacodynamics of nandrolone esters in an oil vehicle in men.
